Treatment of Muckle-Wells syndrome: analysis of two IL-1-blocking regimens

Table 2 Treatment efficacy of anakinra and canakinumab in patients with MWS

IL-1 inhibitor	Anakinra cohort (n= 12)					Canakinumab cohort (n= 14)
	Baseline	Short-term end point^a	Comparison short-term end point, baseline	Long-term end point^b	Comparison long-term end point, baseline	Baseline	Short-term end point^a	Com-parison short-term end point, baseline	Long-term end point^b	Com-parison long-term end point, baseline
Disease activity score (MWS-DAS)
Mean MWS-DAS (stdv)	13 (2.2)	3 (1.0)	0.0005	4 (3.2)	0.0005	6 (1.9)	3 (1.8)	0.002	2 (1.3)	0.0002
Inflammatory markers
Mean ESR in mm/h (stdv)	32 (17)	13 (16)	0.02	10 (5)	0.0005	24 (9.8)	11.9 (4.6)	<0.0001	8.4 (4.8)	<0.0001
Elevated ESR (%) (>22 mm/h)	9 (75)	1 (8)	-	1 (8)	-	9 (64)	0		1 (7)
Mean CRP in mg/dl (stdv)	2.1 (1.3)	0.9 (1.9)	0.09 NS	0.4 (0.5)	0.0005	2.3 (2.1)	0.1 (0.1)	0.001	0.2 (0.3)	0.001
Elevated CRP (%) (>0.5 mg/dl)	11 (92)	4 (33)	-	3 (25)	-	12 (86)	0	-	1 (7)	-
Mean SAA in mg/L (stdv)	36.5 (26.1)	27.5 (70.5)	0.67 NS	6.6 (5.2)	0.001	88.4 (185.1)	3.4 (3.8)	0.01	4.50 (5.8)	0.11 NS
Elevated SAA (%) (>10 mg/L)	11 (92)	4 (33)	-	3 (25)	-	9 (64)	1 (7)	-	1 (7)	-
Mean S100A12 in ng/ml (stdv)	240 (172) (11/12)	142 (57) (11/12)	0.05	273 (330) (11/12)	0.70 NS	284.1 (255.5)	73.4 (51.4)	0.01	76.4 (44.5)	0.01
Elevated S100A12 (%) (>130 ng/ml)	6/11 (55)	6/11 (55)	-	5/11 (45)	-	10 (71)	1 (7)	-	2 (14)	-
Remission (MWS-DAS ≤5 plus normal CRP and SAA)
Patients in remission (%)	NA	8 (67)		9 (75)		NA	13 (93)		13 (93)

Stdv, standard deviation. ^aShort-term end point was 14 days for anakinra and 8 days for canakinumab, based on the specific pharmacokinetic features of each drug. ^bMedian long-term end point was 12 (5 to 14) months for anakinra and 11 (6 to 15) months for canakinumab.

ISSN: 1478-6362